Grant✓ Small businesses may apply
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
National Institutes of Health
- Opportunity #
- PAR-25-183
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.242
- Status
- posted
- Posted
- Nov 26, 2024
- Closes
- Oct 15, 2027
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Small businesses
- •Independent school districts
- •Public housing authorities/Indian housing authorities
- •Private institutions of higher education
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •For profit organizations other than small businesses
- •County governments
- •City or township governments
- •Public and State controlled institutions of higher education
- •Native American tribal governments (Federally recognized)
- •Special district governments
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •State governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.
Contact
National Institutes of Health · grantsinfo@nih.gov